Furthermore, CRYBB1, CEACAM4, and HAMP could serve as prognostic biomarkers or potential drug targets for ccRCC, especially for the combination with sunitinib. This evidence concerns the gene CEACAM4 and nonpapillary renal cell carcinoma.